Alpine Global Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Alpine Global Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-18,701	Closed	-$77K	–	243
2017 Q4	$77K	Buy	+18,701	New	+$81.4K	0.02%	172

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Alpine Global Management's OMED Position: Q1 2018 in Review

Alpine Global Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2018, closing a stake of 18,701 shares — an estimated $77K sold.

Alpine Global Management first reported a position in OMED in Q4 2017 and held it in 1 quarter. The position peaked at $77K in Q4 2017. 66 funds tracked by Wall St. Rank hold OMED as of Q1 2018.

Alpine Global Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Alpine Global Management sold 18,701 OncoMed Pharmaceuticals, Inc. shares in Q1 2018, an estimated $77K.
Alpine Global Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
Alpine Global Management's OncoMed Pharmaceuticals, Inc. position peaked at $77K in Q4 2017.
66 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2018.

Based on Alpine Global Management's 13F filing for Q1 2018, filed 16 May 2018.